This project will examine the connection between variants in the superoxide-generating leukocyte NADPH oxidase 2 (NOX2), genetic susceptibility and pathogenesis of SLE to follow up on our exciting discovery linking leukocyte NADPH oxidase NCF2 H389Q and R395W mutations to human SLE. Our central hypothesis is that SLE is not a single disease entity, but rather represents distinct subtypes based on combination of some of the genetic risk factors. Thus, we hypothesize that lupus linked to reduced NADPH oxidase activity as a consequence of NOX2 functional variants represent a distinct subtype of SLE with specific pathways regulating pathogenesis, unique biomarkers and therefore responsive to specific therapies. In the present study we will determine the overall prevalence of functionally important NADPH oxidase variants in lupus subjects using next generation sequencing (NGS) technologies to detect and validate important new variants in 9 NADPH oxidase genes and determine the extent of the contribution of the NADPH oxidase complex to the genetic predisposition to human SLE (aim 1) and will further analyze the identified and functionally promising H389Q and R395W NCF2 variants (subaims 1.3 and 1.4).
In specific aim 2 we will investigate mechanisms by which reduced NADPH oxidase activity promotes lupus pathogenesis using newly created mouse models of lupus with genetic defects in the NADPH oxidase, including partial deficiency (haploinsufficient NCF2, hypomorphic NCF2) and with deletion of NADPH oxidase in selected myeloid lineages. These mechanistic analyses will be done on several levels: gene expression studies (subaim 2.1) to define biological markers and pathways regulating NOX2 associated lupus; role of type I IFNs in driving pathogenesis (subaim 2.2); role of different cell subsets in driving the process (subaim 2.3); role of NETosis in the pathogenesis (subaim 2.4) and finally assessing potential NOX2 agonists as likely specific treatment modality to this subset of lupus (subaim 2.5).

Public Health Relevance

Lupus is a debilitating multisystem autoimmune disorder, characterized by chronic inflammation and extensive immune dysregulation in multiple organ systems, resulting in significant morbidity and mortality, affecting more than 1.5 million Americans 90% of which are women. Our studies will result in new understanding of the genetics of SLE by pinpointing specific causal mutations in genes, pathways and mechanisms that may result in in new and precise treatment modalities. The results obtained in lupus will apply to many other autoimmune diseases which affect up to 5% of the US population.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR072212-03
Application #
9753928
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Wang, Yan Z
Project Start
2017-08-01
Project End
2022-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089